This article first appeared on GuruFocus .
Release Date: February 11, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Revenue for Q1 2026 increased by 4.8% at constant currencies to 240 million, driven by strong demand across the portfolio.
-
EBITDA grew significantly by 11% to 65 million, resulting in a strong margin of 27.1%, primarily due to high-value solutions.
-
The company launched innovative products like Elio amber vials and prevalidated new polymer cartridges, setting industry benchmarks.
-
Schott Pharma AG & CO KGaA is expanding capacities for high-value solutions in Switzerland and Hungary, focusing on large volume solutions.
-
Net income increased by 12% year on year to 33.3 million, reflecting strong financial performance.
Negative Points
-
Cash flow from operating activities was significantly below the prior year at 3.4 million, impacted by a deferred payment.
-
The drug delivery systems segment saw a decline in EBITDA by 7.3% due to product mix effects and lower production utilization.
-
The reduced use of mRNA vaccines negatively affected polymer syringes, contributing to a slight decline in the segment.
-
Free cash flow amounted to -20 million in the first quarter, mainly impacted by the deferred payment.
-
The company faces ongoing market volatility, which affects its ability to provide specific quarterly guidance.
Q & A Highlights
Q: Can you talk about the level of confidence in the full-year outlook following the positive start to the year, and how do you expect revenues and margins to trend for the remaining quarters? A: We have confirmed our guidance due to the high market volatility. While the start was good, we need to see how the rest of the year develops. We are confident in achieving our guidance. (CEO Andreas Reiser)
Q: Can you discuss the expectations for the DCS segment and whether it is becoming less volatile with better visibility? A: We expect HVS within DCS to remain strong, following our strategy. The demand for sterile solutions, such as vials and cartridges, is high, and we anticipate a higher share of high-value solutions in DCS for the rest of the year. (CEO Andreas Reiser)
Q: Have there been any changes to demand in core DCS, and was growth more in cartridges or vials? A: Core DCS is growing with the market at low single digits. The main growth driver is high-value solutions. Cartridges, especially due to GLP-1 demand, are a significant growth driver, although they are the smallest group within DCS. (CEO Andreas Reiser)
Q: Can you provide insights into the ramp-up process in Switzerland and Hungary and the expected impact on capacity this fiscal year? A: In Switzerland, demand for sterile cartridges is high, exceeding capacity. In Hungary, we are validating lines for glass syringes and expanding sterile cartridge capacity. These projects are on track and will influence sales positively. (CEO Andreas Reiser)
Q: What are the main challenges and sources of market volatility currently? A: Volatility arises from better-than-expected vaccination demand, potential impacts from a syringe client, and strong GLP-1 demand. These factors contribute to uncertainty, but we have had a good start to the year. (CFO Reinard Meyer)
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
